Is there an advantage to venlafaxine in comparison with other antidepressants?

Human Psychopharmacology

Volumn 12, Issue 1, 1997, Pages 53-64

  Benkert, Otto ^a   Gründer, Gerhard ^a   Wetzel, Hermann ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

adrenoceptors; MAOIs; onset of action; SSRIs; tricyclic antidepressants; venlafaxine

Indexed keywords

AMITRIPTYLINE; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OXAPROTILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANOREXIA; ARTICLE; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INSOMNIA; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL;

EID: 0031057446     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199701/02)12:1<53::AID-HUP837>3.0.CO;2-5     Document Type: Article

References (73)

1. Altamura, A. C., Montgomery, S. A. and Wernicke, J. F. (1988). The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. British Journal of Psychiatry, 153 (Suppl. 3), 109-112.
2. Anderson I. M. and Tomenson, B. M. (1995). Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. British Medical Journal, 310, 1433-1438.
3. Baron, B. M., Ogden, A.-M., Siegel, B. W., Stegeman, J., Ursillo, R. C. and Dudley, M. W. (1988). Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine. European Journal of Pharmacology, 154, 125-134.
4. Beasley, C. M., Jr, Bosomworth, J. C. and Wernicke, J. F. (1990). Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacology Bulletin, 26, 18-24.
5. Beasley, C. M., Jr, Holman, S. L. and Potvin, J. H. (1993). Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Annals of Clinical Psychiatry, 5, 199-207.
6. Beasley, C. M., Jr, Sayler, M. E., Bosomworth, J. C. and Wernicke, J. F. (1991). High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. Journal of Clinical Psychopharmacology, 11, 166-174.
7. Benkert, O., Gründer, G., Wetzel, H. and Hackett, D. (1996). A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of Psychiatric Research, in press.
8. Bergstrom, R. F., Peyton, A. L. and Lemberger, L. (1992). Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clinical Pharmacology and Therapeutics 51, 239-248.
9. Bolden-Watson, C. and Richelson, E. (1993). Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences, 52, 1023-1029.
10. Brosen, K., Hansen, H., Nielsen, E., Sindrup, S. H. and Gram, L. F. (1993). Inhibition by paroxetine of desipramine metabolism in extensive but not poor metabolizers of sparteine. European Journal of Clinical Pharmacology, 44, 349-355.
11. Clerc, G. E., Ruimy, P. and Verdeau-Paillés, J. (1994). A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. International Clinical Psychopharmacology, 9, 138-143.
12. Crewe, H. K., Lennard, M. S., Tucker, G. T., et al. (1992). The effect of selective serotonin re-uptake inhibitors on cytochrome-P4502D6 (CYP2D6) activity in human liver microsomes. British Journal of Clinical Pharmacology, 34, 262-265.
13. Cunningham, L. A., Borison, R. L., Carman, J. S., Chouinard, G., Crowder, J. E., Diamond, B. I., Fischer, D. E. and Hearst, E. (1994). A comparison of venlafaxine, trazodone, and placebo in major depression. Journal of Clinical Psychopharmacology, 14, 99-106.
14. Cusack, B., Nelson, A. and Richelson, E. (1994). Binding of antidepressants to human brain receptors: focus on new generation compounds. Psychopharmacology 114, 559-565.
15. Danjou, P. and Hackett, D. (1995). Safety and tolerance profile of venlafaxine. International Clinical Psychopharmacology, 10(Suppl. 2), 15-20.
16. Danish University Antidepressant Group (1986). Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology, 90, 131-138.
17. Danish University Antidepressant Group (1990). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 18, 289-299.
18. de Montigny, C., Grunberg, F., Mayer, A. and Deschenes, J. P. (1981). Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. British Journal of Psychiatry, 138, 252-256.
19. Dierick, M., Ravizza, L., Realini, R. and Martin, A. (1996). A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuropsychopharmacology and Biological Psychiatry, 20, 57-71.
20. Dornseif, B. E., Dunlop, S. R., Potvin, J. H. and Wernicke, J. F. (1989). Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacology Bulletin, 25, 71-79.
21. Dunbar, G. C., Conn, J. B., Fabre, L. F., Feighner, J. P., Fieve, R. R., Mendels, J. and Shrivastava, R. K. (1991). A comparison of paroxetine, imipramine and placebo in depressed out-patients. British Journal of Psychiatry, 159, 394-398.
22. Entsuah, R., Upton, G. V. and Rudolph, R. (1995). Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: a meta-analysis. Human Psychopharmacology, 10, 195-200.
23. Ferguson, J., Khan, A., Kucharik, R., Leventer, S. and Cucci, C. (1994). A placebo-controlled comparative study of the effects of blood pressure and antidepressant efficacy of venlafaxine and imipramine (abstract). Neuropsychopharmacology, 10, 117.
24. Fickinger, M. P., Philipp, M., Benkert, O., Schwarze, H. and Angersbach, J. (1994). Paroxetine in depression: need for dose escalation (abstract). Neuropsychopharmacology, 10(Suppl), 47.
25. Frank, E., Kupfer, D. J., Perel, J. M., Cornes, C., Jarrett, D. B., Mallinger, A. G., Thase, M. E., McEachran, A. B. and Grochocinski, V. J. (1990). Three-year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry, 47, 1093-1099.
26. Freemantle, N., House, A., Song, F., Mason, J. M. and Sheldon, T. A. (1994). Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. British Medical Journal, 309, 249-253.
27. Gerson, S. C., Plotkin, D. A. and Jarvik, L. F. (1988). Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. Journal of Clinical Psychopharmacology, 8, 311-322.
28. Gitlin, M. J. (1994). Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. Journal of Clinical Psychiatry, 55, 406-413.
29. Gram, L. F. (1994). Fluoxetine. New England Journal of Medicine, 331, 1354-1361.
30. Gründer, G., Wetzel, H., Schlösser, R. and Benkert, O. (1996). Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24 hour monitoring. Pharmacopsychiatry, 29, 72-78.
31. Guelfi, J. D., White, C., Hackett, D., Guichoux, J. Y. and Magni, G. (1995). Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of Clinical Psychiatry, 56, 450-458.
32. Härtter, S., Wetzel, H., Hammes, E. and Hiemke, C. (1993). Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology, 110, 302-308.
33. Katon, W., von Korff, M., Lin, T., Bush, T. and Ormel, J. (1992). Adequacy and duration of antidepressant treatment in primary care. Medical Care, 30, 67-76.
34. Khan, A., Rudolph, R., Baumel, B., Ferguson, J., Ryan, P. and Shrivastava, R. (1995). Venlafaxine in depressed geriatric outpatients: An open-label clinical study. Psychopharmacology Bulletin, 31, 753-758.
35. Lecable, P., Letzelter, J.-M., Lichtblau, E., Prak, H., De Ruiter, F., Bruers, Y. and Hackett, D. (1995). An open label evaluation of the clinical acceptability of venlafaxine for general use as an antidepressant. Primary Care and Psychiatry, 1, 119-126.
36. Lydiard, R. B. (1995). Tricyclic-resistant depression; treatment resistance or inadequate treatment? Journal of Clinical Psychiatry, 46, 412-417.
37. Lydiard, R. B., Anton, R. F. and Cunningham, T. (1993). Interactions between sertraline and tricyclic antidepressants. American Journal of Psychiatry, 150, 1125-1126.
38. Magni, G. and Hackett, D. (1992). An open-label evaluation of the long-term safety and clinical acceptability of venlafaxine in depressed patients (abstract). Clinical Neuropharmacology, 15 (Suppl. 1, Part B), 323B.
39. McCombs, J. S., Nichol, M. B., Stimmel, G. L., Sclar, D. A., Beasley, C. M., and Gross, L. S. (1990). The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. Journal of Clinical Psychiatry, 51(6, Suppl.), 60-69.
40. McGrath, P. J., Quitkin, F. M., Harrison, W. and Stewart, J. W. (1984). Treatment of melancholia with tranylcypromine. American Journal of Psychiatry, 141, 288-289.
41. McGrath, P. J., Stewart, J. W., Harrison, W. and Quitkin, F. M. (1987). Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacology Bulletin, 23, 169-172.
42. Mendels, J., Johnston, R., Mattes, J. and Riesenberg, R. (1993). Efficacy and safety of b.i.d doses of venlafaxine in a dose-response study. Psychopharmacology Bulletin, 29, 169-174.
43. Montgomery, S. A., Henry, J., McDonald, G., Dinan, T., Lader, M., Hindmarch, I., Clare, A. and Nutt, D. (1994a). Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. International Clinical Psychopharmacology, 9, 47-53.
44. Montgomery, S. A., Pedersen, V., Tanghoj, P., Rasmussen, C. and Rioux, P. (1994b). The optimal dosing regimen for citalopram - a meta-analysis of nine placebo-controlled studies. International Clinical Psychopharmacology, 9 (Suppl. 1), 35-40.
45. Muth, E. A, Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T. and Sigg, E. B. (1986). Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, and ethylcyclohexanol derivative. Biochemical Pharmacology, 35, 4493-4497.
46. Muth, E. A., Moyer, J. A., Haskins, J. T., Andree, T. H. and Husbands, G. E. M. (1991). Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Development Research, 23, 191-199.
47. Nelson, J. C., Mazure, C. M., Bowers, M. B. and Jatlow, P. (1991). A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Archives of General Psychiatry, 48, 303-307.
48. Nierenberg, A., Feighner, J. P., Rudolph, R., Cole, J. O. and Sullivan, J. (1994). Venlafaxine for treatment-resistant unipolar depression. Journal of Clinical Psychopharmacology, 4, 419-423.
49. NIH Consensus Development Panel (1985). Mood disorders: pharmacologic prevention of recurrences. American Journal of Psychiatry, 142, 469-476.
50. Otton, S. V., Ball, S. E., Cheung, S. W., Inaba, T., Rudolph, R. L. and Sellers, E. M. (1996). Venlafaxine oxidation in vitro is catalysed by CYP2D6. British Journal of Clinical Pharmacology, 41, 149-156.
51. Pollock, B. G., Perel, J. M., Kupfer, D. J., Bowler, K. A. and Miewald, J. M. (1993). Early response patterns associated with successful clomipramine treatment. Journal of Clinical Psychopharmacology, 13, 442-447.
52. Potter, W. Z., Rudorfer, M. V. and Manji, H. (1991). The pharmacologie treatment of depression. New England Journal of Medicine, 325, 633-642.
53. Preskorn, S. H. (1994). Antidepressant drug selection: Criteria and options. Journal of Clinical Psychiatry, 55, 9 (Suppl.), 6-22.
54. Preskorn, S. H. and Fast, G. A. (1992). Therapeutic drug monitoring with antidepressants: efficacy, safety, and cost effectiveness. Journal of Clinical Psychiatry, 52(Suppl.), 23-33.
55. Preskorn, S. H. and Lane, R. M. (1995). Sertraline 50 mg daily: the optimal dose in the treatment of depression. International Clinical Psychopharmacology, 10, 129-141.
56. Quitkin, F. H., Harrison, W., Stewart, J. W., McGrath, P. J., Tricamo, E., Ocepek-Welikson, K., Rabkin, J. G., Wager, S. G., Nunes, E. and Klein, D. F. (1991). Response to phenelzine and imipramine in placebo nonresponders with atypical depression. Archives of General Psychiatry, 48, 319-323.
57. Quitkin, F. M., McGrath, P. J., Stewart, J. W., Harrison, W., Tricamo, E., Wager, S. G., Ocepek-Welikson, K., Nunes, E., Rabkin, J. G. and Klein, D. F. (1990). Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Archives of General Psychiatry, 47, 935-941.
58. Reimherr, F. W., Wood, D. R., Byerley, B., Brainard, J. and Grosser, B. I. (1984). Characteristics of responders to fluoxetine. Psychopharmacology Bulletin, 20, 70-72.
59. Roose, S. P., Glassman, A. H., Walsh, B. T. and Woodring, S. (1986). Tricyclic nonresponders: phenomenology and treatment. American Journal of Psychiatry, 143, 345-348.
60. Roose, S. P., Glassman, A. H., Attia, E. and Woodring, S. (1994). Comparative efficacy of the selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry, 51, 1735-1739.
61. Rudolph, R., Entsuah, R. and Derivan, A. (1991). Early clinical response in depression to venlafaxine hydrochloride (abstract). Biological Psychiatry, 29, 630S.
62. Rudolph, R., Entsuah, R. and Derivan, A. (1994). A low relapse rate confirms the long-term efficacy of venlafaxine in the treatment of major depression (abstract). Neuropsychopharmacology, 10(Suppl.), 105.
63. Schweizer, E., Feighner, J., Mandos, L. and Rickels, K. (1994). Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Journal of Clinical Psychiatry, 55, 104-108.
64. Shrivastava, R., Cohn, C., Crowder, J., Davidson, J., Dunner, D., Feighner, J., Kiev, A. and Patrick, R. (1994). Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. Journal of Clinical Psychopharmacology, 14, 322-329.
65. Spiker, D. G., Perel, J. M., Hanin, I., Dealy, R. S., Griffin, S. J., Soloff, P. H. and Weiss, J. C. (1986). The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology, 6, 339-342.
66. Spiker, D. G., Weiss, J. C., Dealy, R. S., Griffin, S. J., Hanin, J., Neil, J. F., Perel, J. M., Rossi, A. J. and Soloff, P. H. (1985). The pharmacological treatment of delusional depression. American Journal of Psychiatry, 142, 430-436.
67. Stark, P. and Hardison, D. (1985). A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. Journal of Clinical Psychiatry, 46, 53-58.
68. Stassen, H. H., Delini-Stula, A. and Angst, J. (1993). Time course of improvement under antidepressant treatment: a survival-analytical approach. European Neuropsychopharmacology, 3, 127-135.
69. Stassen, H. H., Angst, J. and Delini-Stula, A. (1994). Severity at baseline and onset of improvement in depression. Meta-analysis of imipramine and moclobemide versus placebo. European Psychiatry, 9, 129-136.
70. Thase, M. E., Mallinger, A. G., McKnight, D. and Himmelhoch, J. M. (1992). Treatment of imipramine-resistant recurrent depression: IV. A double-blind, cross-over study of tranylcypromine in anergic bipolar depression. American Journal of Psychiatry, 149, 195-198.
71. Tollefson, G. D. and Holman, S. L. (1993). Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. International Clinical Psychopharmacology, 8, 253-259.
72. Tollefson, G. D. and Holman, S. L. (1994). How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. International Clinical Psychopharmacology, 9, 245-250.
73. Weilberg, J. B., Rosenbaum, J. F., Biederman, J., Sachs, G. S., Pollack, M. H. and Kelly, K. (1989). Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. Journal of Clinical Psychiatry, 50, 447-449.